Substantial Changes and Corrections: Four Device Categories, Two Company Categories, Five Corrections

1. Key takeaways

Article 43 of Decreto Ejecutivo N° 490 divides the substantial changes (cambios sustanciales) affecting medical devices into four device categories and two company categories. Article 44 confines corrections (corrección) to five kinds of clerical error. The two are handled differently. Any change at any stage from design to commercial delivery must be notified to DNDM, first by simple copy with the apostilled original filed within three months. A substantial change requires a fresh CCT application. A correction is raised in the donde dice / debe decir format, stating what the text currently says and what it should say.

• Notification is universal, classification is separate — every change is notified, and only then is the question asked whether it is substantial.
• Four device triggers — origin and manufacturing, quality control and manufacturing procedures, design including software, and intended use or shelf life.
• Two company triggers — a change of company information such as the trade name, and a change of manufacturer information such as the manufacturing site.
• Three-month apostille window — the simple copy opens the notification, but the certified original must follow, and the obligation is not discharged until it does.
• New application, not an amendment — a substantial change is processed as a new CCT application rather than as a variation of the existing one.
• Five correction types — spelling, units of measure, medical or technical terminology, terms written in another language, and other cases determined by DNDM according to risk level.

2. Legal basis

Article 43 of DE 490 of 4 October 2019 imposes the duty to keep the file current, defines the notification mechanism, requires a new CCT for substantial changes and enumerates the device and company triggers. Article 44 governs corrections to a CCT or CVT that remains in force and limits them to five categories of drafting error.

3. Expert insights

Insight one: the duty to notify any change covers the whole lifecycle. The official text reads: Todo cambio que se realice a un Dispositivo Médico, en cualquiera de sus fases desde el diseño hasta su comercialización y entrega al usuario final debe ser notificada. That is any change at any stage, from design to delivery to the final user. It is stricter than the familiar rule in many markets that only reportable or substantial changes must be filed, because Panama requires notification of everything first and only then asks which items are substantial and require a new application. A supplier that filters changes internally before notifying is applying the wrong test.

Insight two: the three-month window to file the certified original is a deliberate buffer. The second paragraph allows the notification to be opened with a simple copy, with the apostilled original following within three months. The design acknowledges how long authentication actually takes, and it follows the same logic as the 180 working day buffer that DE 1689 provided during the COVID period. The operational implication is that the apostille process should start on the day the simple copy is filed. Three months is quickly consumed by notarial certification, consular or apostille processing and courier transit, and the obligation to file the original is not suspended while those steps are pending.

Insight three: the third device trigger puts software specifications inside design change, which matters for software-bearing products. The official text lists El diseño del dispositivo, incluyendo sus características de desempeño, principios de operación y especificación de materiales, de fuentes de energía, de software y de accesorios. A change to software specifications is a design change and therefore substantial. Article 19 of Ley 90 provides separately that software and other updates which do not alter the function of the device do not require a change or update of the registration. Read together, the position is that a software change altering function is substantial, while a change that does not alter function does not trigger the requirement (practical estimate; borderline cases should be confirmed).

Insight four: Article 44 separates typographical error from substantive change. The five correction categories, namely spelling, written units of measure, written terminology, terms in other languages and other cases identified by DNDM, are all questions of expression rather than substance, and they are raised in the donde dice / debe decir format. The value of the mechanism is that a spelling mistake does not have to be routed through a change procedure. The fifth category, however, leaves the boundary to DNDM acting by risk level, so the discretion available is wider for higher-risk devices, and the safe assumption is that anything capable of affecting the interpretation of the label, the intended use or the technical specification will be treated as substance rather than expression.

4. Practical recommendations

• Maintain a change register that records every change, however minor, and notify DNDM by simple copy before assessing classification.
• Start the apostille process on the day the simple copy is filed, so that the original is lodged inside the three-month window.
• Where any element of the fourth paragraph of Article 43 is engaged, process a new CCT application rather than a notification.
• For software changes, determine first whether device function is altered, then choose between notification and substantial change on that basis.
• Use the Article 44 correction form for genuinely clerical errors, in the donde dice / debe decir format, and do not use it to disguise a substantive change.
• Keep evidence of the notification date, since it establishes when the three-month clock began to run.

5. Verification checklist

• □ Change register covers every stage from design to delivery
• □ Simple copy notified and apostilled original filed within three months
• □ Device substantial change assessed against the four categories in Article 43, fourth paragraph
• □ Company substantial change assessed against the two categories in Article 43, fifth paragraph
• □ Substantial change processed as a new CCT application
• □ Clerical errors raised on the Article 44 correction form
• □ Documents kept up to date throughout CCT or CVT validity (Article 43, first paragraph)

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Panamanian market. Our team manages Ministry of Health (MINSA) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com